(Circulation. 2000;101:2721.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Division of Pediatric Cardiology and Department of Obstetrics, University Medical Center, Utrecht, the Netherlands (M.A.O., M.M.M., P.S., G.H.A.V., E.J.M.); the Division of Pediatric Cardiology, Yale New Haven Hospital, Yale University School of Medicine, New Haven, Conn (C.S.K.); and the Childrens Heart Center, University Hospital Nijmegen, Nijmegen, the Netherlands (L.K.).
Correspondence to Erik J. Meijboom, MD, PhD, Department of Cardiology, University Medical Center, KG 01.3190/PO Box 85090, 3508 AB, Lundlaan 6, 3584 EA, Utrecht, The Netherlands. E-mail e.meijboom{at}azu.nl
BackgroundFetal tachycardia may cause hydrops fetalis and lead to fetal death. No unanimity of opinion exists regarding the optimum treatment. This study evaluates our experience with transplacental sotalol therapy to treat fetal tachycardias in terms of safety and efficacy.
Methods and ResultsThe charts of 21 patients who were treated with sotalol for fetal tachycardia were reviewed. Ten fetuses had atrial flutter (AF), 10 had supraventricular tachycardia (SVT), and 1 had VT. Hydrops fetalis was present in 9 fetuses. Drug treatment was successful in establishing sinus rhythm in 8 of 10 fetuses with AF and in 6 of 10 fetuses with SVT. The mortality rate in this study was 19% (4 of 21 fetuses; 3 had SVT and 1 had AF); 3 deaths occurred just days after the initiation of sotalol therapy, and 1 occurred after a dosage increase. At birth, tachycardia was present in 6 infants. Two patients who converted to sinus rhythm in utero suffered from neurologic pathology postnatally.
ConclusionsFetal tachycardia is a serious condition in which treatment should be initiated, especially in the presence of hydrops fetalis. The high success rate in fetuses with AF suggests that sotalol should be considered a drug of first choice to treat fetal AF. The low conversion rate and the fact that 3 of the 4 deaths in this study occurred in fetuses with SVT indicate that the risks of sotalol therapy outweigh the benefits in this group and that sotalol should, therefore, be limited in the treatment of fetal SVT.
Key Words: tachycardia arrhythmia maternal-fetal exchange sotalol hydrops fetalis
This article has been cited by other articles:
![]() |
H. R. Singh, S. Garekar, M. L. Epstein, and T. L'Ecuyer Neonatal Supraventricular Tachycardia (SVT) NeoReviews, July 1, 2005; 6(7): e339 - e350. [Full Text] [PDF] |
||||
![]() |
J. F. Strasburger, B. F. Cuneo, M. M. Michon, N. L. Gotteiner, B. J. Deal, S. N. McGregor, M. A. Oudijk, E. J. Meijboom, L. Feinkind, M. Hussey, et al. Amiodarone Therapy for Drug-Refractory Fetal Tachycardia Circulation, January 27, 2004; 109(3): 375 - 379. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Oudijk, J. M. Ruskamp, F. F. T. Ververs, E. B. Ambachtsheer, P. Stoutenbeek, G. H. A. Visser, and E. J. Meijboom Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics J. Am. Coll. Cardiol., August 20, 2003; 42(4): 765 - 770. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Krapp, T Kohl, J M Simpson, G K Sharland, A Katalinic, and U Gembruch Review of diagnosis, treatment, and outcome of fetal atrial flutter compared with supraventricular tachycardia Heart, August 1, 2003; 89(8): 913 - 917. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |